{"protocolSection":{"identificationModule":{"nctId":"NCT02147444","orgStudyIdInfo":{"id":"EXPAND study"},"secondaryIdInfos":[{"id":"UMIN000009376","type":"OTHER","domain":"UMIN"}],"organization":{"fullName":"Tohoku University","class":"OTHER"},"briefTitle":"Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation","officialTitle":"Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice","acronym":"EXPAND"},"statusModule":{"statusVerifiedDate":"2014-05","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-11"},"primaryCompletionDateStruct":{"date":"2016-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2014-05-12","studyFirstSubmitQcDate":"2014-05-21","studyFirstPostDateStruct":{"date":"2014-05-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-05-21","lastUpdatePostDateStruct":{"date":"2014-05-26","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hiroaki Shimokawa, MD, PhD","investigatorTitle":"MD, PhD, Department of Cardiovascular Medicine","investigatorAffiliation":"Tohoku University"},"leadSponsor":{"name":"Tohoku University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism, namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese clinical practice."},"conditionsModule":{"conditions":["Non-valvular Atrial Fibrillation"],"keywords":["Rivaroxaban","Non-valvular atrial fibrillation","NOAC","Xa inhibitor"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"2 Years","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":7000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Non-valvular atrial fibrillation","description":"* Patients diagnosed with non-valvular atrial fibrillation\n* Patients who are treated or will be treated with rivaroxaban"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Combinations of symptomatic stroke (ischemic or hemorrhagic) and systemic embolism","description":"Primary efficacy endpoint","timeFrame":"up to March/2016"},{"measure":"Clinically significant hemorrhagic events (massive hemorrhage in accordance with the ISTH classification)","description":"Primary safety endpoint","timeFrame":"up to March/2016"}],"secondaryOutcomes":[{"measure":"Combinations of symptomatic stroke (ischemic or hemorrhagic), systemic embolism, myocardial infarction and cardiovascular death","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Symptomatic ischemic stroke","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Symptomatic hemorrhagic stroke","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Systemic embolism","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Acute myocardial infarction/unstable angina pectoris","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Cardiovascular death","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Deep vein thrombosis/pulmonary thromboembolism","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Transient ischemic attack","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Interventional/surgical treatment","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"All-cause death","description":"Secondary efficacy endpoints","timeFrame":"up to March/2016"},{"measure":"Clinically insignificant hemorrhagic events (hemorrhagic events other than clinically significant hemorrhagic events)","description":"Secondary safety endpoint","timeFrame":"up to March/2016"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients who meet all the criteria below\n\n* Patients aged over 20 years\n* Patients diagnosed with non-valvular atrial fibrillation\n* Patients who are treated or will be treated with rivaroxaban\n* Patients from whom written informed consent has been obtained\n\nExclusion Criteria:\n\nPatients who meet any of the criteria below\n\n* The following patients in whom rivaroxaban is contraindicated for use\n* Patients with a history of allergies to the ingredients contained in this drug\n* Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events)\n* Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh classification)\n* Patients having renal failure (creatinine clearance: \\<15 mL/min)\n* Women who are or are likely to be pregnant\n* Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir)\n* Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Non-valvular atrial fibrillation (In the present study, non-valvular atrial fibrillation refers to atrial fibrillation without a history of prosthetic valve replacement or mitral valve stenosis.)","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Koji Fukuda, M.D., Ph. D","role":"CONTACT","phone":"+81-22-717-7153","email":"fukuda@cardio.med.tohoku.ac.jp"}],"overallOfficials":[{"name":"Hiroaki Shimokawa, MD, PhD","affiliation":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine","role":"STUDY_CHAIR"}],"locations":[{"facility":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine","status":"RECRUITING","city":"Sendai","state":"Miyagi","zip":"980-6574","country":"Japan","contacts":[{"name":"Koji Fukuda, MD, PhD","role":"CONTACT","phone":"+81-22-717-7153","email":"fukuda@cardio.med.tohoku.ac.jp"},{"name":"Hiroaki Shimokawa, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":38.26667,"lon":140.86667}}]},"referencesModule":{"seeAlsoLinks":[{"label":"EXPAND study home page","url":"http://cms.captool.jp/expand/"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"},{"id":"D000014652","term":"Vascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M463","name":"Rivaroxaban","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}